吉非替尼在晚期肺腺癌中的临床观察

gefitinib’s Clinical observationin in advanced lung cancer

目的观察单药吉非替尼在晚期肺腺癌中的临床效果和安全性。方法对24例经病理证实的肺腺癌患者,因条件有限未行EGFR突变基因检测,应用吉非替尼250mg/d,评价其疗效、无进展生存期(PFS)长短及不良反应。结果不吸烟女性的疾病控制率占所有女性病例数的60.0%,男性吸烟患者为33.3%。PFS女性为5.8月,男性为2.1月,皮疹在有效患者中发生率70.0%,无效患者中发生率35.7%。结论在不能进行基因检测的情况下,吉非替尼通过优势人群选择能达到较高的治疗目标,皮疹发生可能与治疗疗效有关。

Objective To investigate clinical efficacy and safety of. gefitinib in patient with advanced lung adenocarcinoma. Methods A total nember of 24 adults advanced ung adenocarcinoma patients,without EGFR gene mutation detection,were given orally gefitinib 250mg daily,and were followed up to estimate currentive effect,progression free survival( PFS) and its influencing factors. Results The disease control rate in Nosmoking women was 60. 0% ,in male patients was 33. 3% . PFS in females was 5. 8 months,in males was 2. 1 months,rash in patients occurred was 70. 0% ,with an incidence rate of 57. 1% in valid. Conclusion gefitinib has a good curative effect on the treatment in patients with famal,non-smoking,Asian,adenocarcinoma.